Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by dmacdon Mar 05, 2019 7:48pm

62 Views

Post# 29446865

RE:RE:RE:Bozo mgmt?

SP will stumble along until it pops. Could be dead money for a year or two but good risk reward with a 3 year lookout. Timing it perfectly might be tough. Yofoto buy in price was my reason to dip in. We knew the payout will not be tomorrow. Sheisido is the dark horse and might be a faster lever but yofoto will be bigger. Sheisido is not in our control so you need to accept that.

Bullboard Posts

Canadian artificial intelligence ETFs